Analysts Split on Payments, Biotech, Airlines

Morgan Stanley cut Global Payments to Hold from Buy on Monday. The fintech firm carries a $65 price target. Short interest sits at 7.5% of free float — elevated for the sector.

Biotech saw a brighter call. Analysts upgraded Incyte Corporation to a higher rating. The consensus target now stands at $110.17. The $19.6 billion biopharma has short interest of 6.5% of free float. The upgrade moves one analyst from Sell to Hold in the consensus.

Airlines dominated the target-price action. Analysts lifted targets on both Delta Air Lines and United Airlines Holdings. Delta's consensus target rose to $82.61. United's moved to $132.29. Both carriers saw broad Buy consensus unchanged. 23 analysts rate United a Buy with none recommending Sell.

Steel stocks drew mixed attention. Morgan Stanley raised its target on Steel Dynamics to $270 from $227. Meanwhile Nucor Corporation also saw its average target edge higher to $259.88.

Accenture lost a recommendation entirely. Its average target fell sharply to $185.25 from $197.65 — a nearly $12 drop per share with no new Buy or Sell added to fill the gap.